natgillin/translations-raw huggingface dataset:
Clopidogrel/Acetylsalicylic acid Teva should not affect your ability to drive or to use machines.
Zdravilo Klopidogrel/acetilsalicilna kislina Teva ne bi smelo vplivati na vašo sposobnost upravljanja vozil in strojev.
Clopidogrel/Acetylsalicylic acid Zentiva
Klopidogrel/acetilsalicilna kislina Zentiva
Clopidogrel/Acetylsalicylic acid Zentiva 75 mg/100 mg
Klopidogrel/acetilsalicilna kislina Zentiva 75 mg/100 mg
Clopidogrel/Acetylsalicylic acid Zentiva 75 mg/100 mg film-coated tablets (tablets) are oval, slightly biconvex, light pink, engraved on one side with ‘C75’ and ‘A100’on the other side.
Zdravilo Klopidogrel/acetilsalicilna kislina Zentiva 75 mg/100 mg filmsko obložene tablete (tablete) so ovalne, rahlo bikonveksne, svetlo rožnate, z vtisnjeno oznako «C75» na eni strani in «A100» na drugi strani.
Clopidogrel/Acetylsalicylic acid Zentiva 75 mg/100 mg tablet clopidogrel/acetylsalicylic acid
Klopidogrel/acetilsalicilna kislina Zentiva 75 mg/100 mg tablete klopidogrel/acetilsalicilna kislina
Clopidogrel/Acetylsalicylic acid Zentiva 75 mg/100 mg tablets clopidogrel/acetylsalicylic acid
Klopidogrel/acetilsalicilna kislina Zentiva 75 mg/100 mg tablete klopidogrel/acetilsalicilna kislina
Clopidogrel/Acetylsalicylic acid Zentiva 75 mg/75 mg
Klopidogrel/acetilsalicilna kislina Zentiva 75 mg/75 mg
Clopidogrel/Acetylsalicylic acid Zentiva 75 mg/75 mg film-coated tablets
Klopidogrel/acetilsalicilna kislina Zentiva 75 mg/75 mg filmsko obložene tablete
Clopidogrel/Acetylsalicylic acid Zentiva 75 mg/75 mg film-coated tablets (tablets) are oval, slightly biconvex, yellow, engraved on one side with ‘C75’ and ‘A75’on the other side.
Zdravilo Klopidogrel/acetilsalicilna kislina Zentiva 75 mg/75 mg filmsko obložene tablete (tablete) so ovalne, rahlo bikonveksne, rumene, z vtisnjeno oznako «C75» na eni strani in «A75» na drugi strani.
Clopidogrel/Acetylsalicylic acid Zentiva 75 mg/75 mg film-coated tablets clopidogrel /acetylsalicylic acid
Klopidogrel/acetilsalicilna kislina Zentiva 75 mg/75 mg filmsko obložene tablete klopidogrel in acetilsalicilna kislina
Clopidogrel/Acetylsalicylic acid Zentiva 75 mg/75 mg film-coated tablets clopidogrel/acetylsalicylic acid
Klopidogrel/acetilsalicilna kislina Zentiva 75 mg/75 mg filmsko obložene tablete klopidogrel/acetilsalicilna kislina
Clopidogrel/Acetylsalicylic acid Zentiva 75 mg/75 mg tablet clopidogrel/acetylsalicylic acid
Klopidogrel/acetilsalicilna kislina Zentiva 75 mg/75 mg tablete klopidogrel/acetilsalicilna kislina
Clopidogrel/Acetylsalicylic acid Zentiva 75 mg/75 mg tablets clopidogrel/acetylsalicylic acid
Klopidogrel/acetilsalicilna kislina Zentiva 75 mg/75 mg tablete klopidogrel/acetilsalicilna kislina
Clopidogrel/Acetylsalicylic acid Zentiva contains clopidogrel and acetylsalicylic acid (ASA) and belongs to a group of medicines called antiplatelet medicinal products.
Klopidogrel/acetilsalicilna kislina Zentiva vsebuje klopidogrel in acetilsalicilno kislino (ASA) in spada v skupino zdravil, ki se imenujejo zaviralci agregacije trombocitov.
Clopidogrel/Acetylsalicylic acid Zentiva contains hydrogenated castor oil
Zdravilo Klopidogrel/acetilsalicilna kislina Zentiva vsebuje hidrogenirano ricinusovo olje.
Clopidogrel/Acetylsalicylic acid Zentiva contains lactose
Zdravilo Klopidogrel/acetilsalicilna kislina Zentiva vsebuje laktozo.
Clopidogrel/Acetylsalicylic acid Zentiva has no or negligible influence on the ability to drive and use machines.
Zdravilo Klopidogrel/acetilsalicilna kislina Zentiva nima ali ima zanemarljiv vpliv na sposobnost za vožnjo in upravljanje strojev.
Clopidogrel/Acetylsalicylic acid Zentiva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA).
Zdravilo Klopidogrel/acetilsalicilna kislina Zentiva je indiciran za preprečevanje aterotrombotičnih dogodkov pri odraslih bolnikih, ki že jemljejo klopidogrel in acetilsalicilno kislino (ASA).
Clopidogrel/Acetylsalicylic acid Zentiva is indicated for the prevention of atherothrombotic events in adult patients already taking both clopidogrel and acetylsalicylic acid (ASA).
Zdravilo Klopidogrel/acetilsalicilna kislina Zentiva je indicirano za preprečevanje aterotrombotičnih dogodkov pri odraslih bolnikih, ki že jemljejo klopidogrel in acetilsalicilno kislino (ASA).
Clopidogrel/Acetylsalicylic acid Zentiva is supplied in cardboard cartons containing:
Zdravilo Klopidogrel/acetilsalicilna kislina Zentiva je na voljo v kartonskih škatlah, ki vsebujejo:
Clopidogrel/Acetylsalicylic acid Zentiva is taken by adults to prevent blood clots forming in hardened arteries which can lead to atherothrombotic events (such as stroke, heart attack, or death).
Klopidogrel/acetilsalicilna kislina Zentiva jemljejo odrasli za preprečevanje nastanka krvnih strdkov v otrdelih krvnih žilah ki lahko vodi do aterotrombotičnih dogodkov (kot so kap, srčni napad ali smrt).
Clopidogrel/Acetylsalicylic acid Zentiva is used following initiation of therapy with clopidogrel and ASA given separately.
Zdravilo Klopidogrel/acetilsalicilna kislina Zentiva se uporablja po začetni ločeni terapiji s klopidogrelom in ASA:
Clopidogrel/Acetylsalicylic acid Zentiva should be given as a single daily 75 mg/100 mg dose.
Zdravilo Klopidogrel/acetilsalicilna kislina Zentiva se mora dajati kot enkratni dnevni odmerek 75 mg/75 mg.
Clopidogrel/Acetylsalicylic acid Zentiva should be given as a single daily 75 mg/75 mg dose.
Zdravilo Klopidogrel/acetilsalicilna kislina Zentiva se mora dajati kot enkratni dnevni odmerek 75 mg/75 mg.
Clopidogrel/Acetylsalicylic acid Zentiva should not affect your ability to drive or to use machines.
Zdravilo Klopidogrel/acetilsalicilna kislina Zentiva ne bi smelo vplivati na vašo sposobnost za vožnjo ali upravljanje strojev.
Clopidogrel:
UKlopidogrel:
Clopidogrel: In a phase I study in young healthy male volunteers, the concomitant administration of dabigatran etexilate and clopidogrel resulted in no further prolongation of capillary bleeding times compared to clopidogrel monotherapy.
Klopidogrel: V I. fazi študije, v kateri so sodelovali mladi zdravi prostovoljci, se pri sočasnem dajanju dabigatran eteksilata in klopidogrela čas kapilarne krvavitve v primerjavi z monoterapijo s klopidogrelom ni dodatno podaljšal.
Clopidogrel: In a phase I study in young healthy male volunteers, the concomitant administration of dabigatran etexilate and clopidogrel resulted in no further prolongation of capillary bleeding times compared to clopidogrel monotherapy.
Klopidogrel: V preskušanju I. faze, v katerem so sodelovali mladi zdravi prostovoljci, se pri sočasnem dajanju dabigatran eteksilata in klopidogrela čas kapilarne krvavitve v primerjavi z monoterapijo s klopidogrelom ni dodatno podaljšal.
Clorazepate
klorazepat
Clorazepate Diazepam Estazolam
Klorazepat Diazepam Estazolam
Clorazepate Diazepam Estazolam Flurazepam Lorazepam Triazolam Zolpidem
buspiron klorazepat diazepam estazolam flurazepam lorazepam triazolam zolpidem
clorazepate or diazepam - used to make you calmer encainide, flecanide, propafenone, or quinidine - used for uneven heartbeat problems.
klorazepat ali diazepam – uporabljata se za pomiritev enkainid, flekanid, propafenon ali kinidin - uporabljajo se pri težavah z nerednim bitjem srca
clorazepate, diazepam, estazolam, flurazepam, triazolam or oral (taken by mouth) midazolam (used to help you sleep and/or relieve anxiety);
klorazepat, diazepam, estazolam, flurazepam, triazolam ali peroralni (zaužiti) midazolam (uporabljajo se proti nespečnosti in/ali za odpravljanje tesnobnosti),
close adhesive label and seal discard with solid waste
pokrijte in zalepite zavržite s smetmi
Close blood glucose monitoring is therefore recommended.
Zato je priporocljivo natancno nadzorovanje glukoze v krvi.
Close clinical and biological (INR measurement) monitoring is recommended when warfarin and tipranavir are combined.
Pri kombiniranju teh zdravil je treba bolnika skrbno klinično in biološko spremljati (z merjenjem INR).
Close clinical and laboratory monitoring is recommended when giving digoxin concomitantly with Possia (see section 4.5).
Med sočasno uporabo digoksina in zdravila Possia je priporočljivo natančno klinično in laboratorijsko spremljanje (glejte poglavje 4.5).
close clinical follow-up should be undertaken measurement of liver enzymes (ASAT, ALAT, gamma GT and alkaline phosphatase) and bilirubin, should be performed at frequent intervals:
opravljati je treba skrbno klinično spremljanje; redno je treba izvajati meritve jetrnih encimov (ASAT, ALAT, gama GT ter alkalne fosfataze) in bilirubina:
Close clinical monitoring
Med sočasno uporabo
Close clinical surveillance (looking for signs of bleeding or anaemia) is recommended throughout the treatment period, especially if risk factors are combined (see section 5.1).
Natančen klinični nadzor (da bi odkrili znake krvavitve ali anemije) priporočamo ves čas zdravljenja, zlasti pri kombinaciji dejavnikov tveganja (glejte poglavje 5.1).
Close clinical surveillance (looking for signs of bleeding or anaemia) is recommended throughout the treatment period, especially if risk factors are combined (see section 5.1).
Natančen klinični nadzor (da bi odkrili znake krvavitve ali anemije) priporočamo ves čas zdravljenja, še zlasti pri kombinaciji dejavnikov tveganja (glejte poglavje 5.1).
Close clinical surveillance is recommended when dabigatran etexilate is combined with amiodarone and particularly in the occurrence of bleeding, notably in patients having a mild to moderate renal impairment.
Kadar dabigatran eteksilat kombiniramo z amiodaronom, je potreben natančen klinični nadzor, zlasti če se pojavi krvavitev, in predvsem pri bolnikih z blago do zmerno ledvično okvaro.
Close clinical surveillance is recommended when dabigatran etexilate is combined with amiodarone and particularly in the occurrence of bleeding, notably in patients having a mild to moderate renal impairment.
Kadar dajemo dabigatran eteksilat sočasno s amiodaronom je potrebno natančno klinično spremljanje za primer pojava krvavitve , še posebej pri bolnikih z blago do zmerno ledvično okvaro.
Close clinical surveillance is recommended when dabigatran etexilate is combined with quinidine and particularly in the occurrence of bleeding, notably in patients having a mild to moderate renal impairment.
Kadar dabigatran eteksilat kombiniramo s kinidinom, je potreben natančen klinični nadzor, zlasti če se pojavi krvavitev, in predvsem pri bolnikih z blago do zmerno ledvično okvaro.
Close clinical surveillance is recommended when dabigatran etexilate is combined with quinidine and particularly in the occurrence of bleeding, notably in patients having a mild to moderate renal impairment.
Kadar dajemo dabigatran eteksilat sočasno s kinidinom je potrebno natančno klinično spremljanje za primer pojava krvavitve , še posebej pri bolnikih z blago do zmerno ledvično okvaro.
Close clinical surveillance is recommended when dabigatran etexilate is combined with quinidine and particularly in the occurrence of bleeding, notably in patients having a mild to moderate renal impairment.
Ob sočasnem jemanju kinidina z dabigatran eteksilatom je potrebno natančno klinično spremljanje, še posebej ob pojavu krvavitev, zlasti pri bolnikih z blago do zmerno ledvično okvaro.
Close clinical surveillance is recommended when dabigatran etexilate is combined with verapamil and particularly in the occurrence of bleeding, notably in patients having a mild to moderate renal impairment.
Kadar dabigatran eteksilat kombiniramo s verapamilom, je potreben natančen klinični nadzor, zlasti če se pojavi krvavitev, in predvsem pri bolnikih z blago do zmerno ledvično okvaro.
Close clinical surveillance is recommended when dabigatran etexilate is combined with verapamil and particularly in the occurrence of bleeding, notably in patients having a mild to moderate renal impairment.
Kadar se dabigatran eteksilat jemlje sočasno z verapamilom je potrebno natančno klinično spremljanje, še posebej ob pojavu krvavitev, posebej pri bolnikih z blago do zmerno okvaro ledvic.
Close contact with infants and pregnant women should be restricted during the initial 24 hours following the injection.
V prvih 24 urah po injiciranju je treba omejiti neposreden stik z dojenčki in nosečnicami.
Close contacts who are pregnant or immunocompromised should not change the patient’s dressing or clean their injection site.
Osebe, ki so v tesnem stiku z bolnikom in so noseče ali imunokompromitirane, ne smejo menjati bolnikovih povojev ali čistiti njegovih mest injiciranja.
Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter.
Med prehodom in v prvih tednih po njem je priporočljivo natančno kontrolirati presnovo.
Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter.
Med prehodom in v prvih tednih po njem je priporočljivo natančno nadzirati presnovo.
Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter;
Med prehodom in v prvih tednih po njem je priporočljivo natančno kontrolirati presnovo.
Close monitoring for
Priporočeno je skrbno
Close monitoring for an effect on the QTc interval is advisable and a baseline ECG is recommended prior to initiating therapy with Tasigna and as clinically indicated.
Priporočljivo je natančno spremljanje učinka na interval QTc ter opravljanje izhodiščne EKG preiskave pred začetkom zdravljenja z zdravilom Tasigna in kadar je klinično potrebno.
Close monitoring for clinical signs and symptoms of CHF should be performed, especially in patients with cardiac risk factors and/or history of coronary artery disease.
Bolnike je treba skrbno spremljati glede kliničnih znakov in simptomov kongestivnega srčnega popuščanja, zlasti bolnike s srčnimi dejavniki tveganja in/ali anamnezo koronarne bolezni.
Close monitoring for signs of rilpivirine toxicity and possibly also dose adjustment of rilpivirine is recommended when co- administered with Aptivus/ritonavir.
Pri sočasni uporabi z zdravilom Aptivus/ritonavirjem priporočajo natančno spremljanje zdravljenja zaradi možnih znakov toksičnosti rilpivirina in potrebe po zmanjšanju njegovega odmerjanja.
Close monitoring is recommended if this medicinal product is administered with Daklinza in combination with sofosbuvir (see sections 4.4 and 4.8).
Kadar se to zdravilo uporablja sočasno z zdravilom Daklinza v kombinaciji s sofosbuvirjem, se priporoča skrbno spremljanje (glejte poglavji 4.4 in 4.8).
Close monitoring is recommended in patients with several of these risk factors.
Priporočljivo je skrbno spremljanje bolnikov z več dejavniki tveganja.
Close monitoring is required of any patients who develop liver enzyme elevation with appropriate dose adjustment or discontinuation.
Bolnike, pri katerih se je pojavilo povišanje jetrnih encimov, je treba pozorno spremljati in po potrebi prilagoditi odmerek ali prekiniti zdravljenje.
Close monitoring is therefore needed in patients treated with Aptivus, co-administered with low dose ritonavir (see section 4.4).
Bolnike, ki prejemajo zdravilo Aptivus ob hkratnih majhnih odmerkih ritonavirja, moramo zato skrbno spremljati (glejte poglavje 4.4).
Close monitoring of
Pri sočasni uporabi
Close monitoring of
Priporočljivo je pozorno
Close monitoring of glycaemic control should be considered (see section 4.4).
Natančno je treba spremljati urejenost glikemije (glejte poglavje 4.4).
Close monitoring of glycaemic control should be considered (see section 4.4).
Urejenost glikemije je treba natančno kontrolirati (glejte poglavje 4.4).
Close monitoring of immunosuppressant concentrations for at least
koncentracij imunosupresiva vsaj
Close monitoring of immunosuppressant concentrations for at least
študiji, pri čemer pa so bile
Close monitoring of the patient's virologic response should be excercised.
Pri bolniku je treba skrbno spremljati virusni odziv.
Close monitoring of the pregnancy and clinical manifestations of Gaucher disease is necessary for the individualization of dose according to the patient’s needs and therapeutic response.
Za individualizacijo odmerkov glede na bolnikove potrebe in odziv na zdravljenje je treba skrbno nadzirati nosečnost in klinične manifestacije Gaucherjeve bolezni.
Close monitoring of toxicities is required in patients receiving trabectedin in combination with potent CYP3A4 inhibitors (e.g. oral ketoconazole, fluconazole, ritonavir, clarithromycin or aprepitant) and such combinations should be avoided if possible.
Skrbno spremljanje toksičnosti je potrebno pri bolnikih, ki prejemajo trabektedin v kombinaciji z močnimi zaviralci CYP3A4 (npr. peroralni ketokonazol, flukonazol, ritonavir, klaritromicin ali aprepitant), in takšnim kombinacijam se je treba izogniti, če je to mogoče.
Close safety monitoring is advised for patients on continuous renal replacement therapy, due to limited clinical data and an expected increased exposure to doripenem-M-1 metabolite (see section 4.4).
Zaradi omejenih kliničnih podatkov in pričakovane zvečane izpostavljenosti presnovku doripenema M-1 (glejte poglavje 4.4) je priporočljivo skrbno spremljanje bolnikov na kontinuiranem nadomestnem zdravljenju končne ledvične odpovedi.
Close the bottle again
Ponovno zaprite steklenico
Close the bottle cap firmly immediately after use
Takoj po uporabi kapalni vsebnik spet tesno zaprite z zaporko.
Close the bottle cap firmly immediately after use.
Takoj po uporabi zamašek plastenke trdno zaprite.
Close the bottle tightly with the cap.
Stekleničko tesno zaprite z zaporko.
Close the bottle with the child safety bottle cap after each use.
Po vsaki uporabi zaprite steklenico z za otroke varno zaporko.
Close the bottle with the plastic screw cap after every usage.
Zaprite steklenico s plastično navojno zaporko po vsaki uporabi.
Close the bottle with the plastic screw cap.
Zaprite steklenico s plastično navojno zaporko.
Close the bottle, keep it safe
Zaprite steklenico in jo shranite na varno
Close the bottle.
Zaprite steklenico.
Close the inhaler
Zaprite inhalator
Close the inhaler
Zaprite pokrovček inhalatorja
Close the inhaler and replace the cap.
Zaprite inhalator in ga pokrijte z zaporko.
Close the inhaler and rinse your mouth
Bolnik naj zapre inhalator in si splakne usta
Close the inhaler and rinse your mouth if possible
Zaprite inhalator in si, če je možno, splaknite usta.
Close the inhaler until you hear a “click”.
Ko zaprete inhalator, slišite "klik".
Close the inhaler until you hear a “click”.
Ko zaprete inhalator, slišite “klik”.
Close the inhaler.
Zaprite inhalator.
Close the inhaler:
Zaprite inhalator:
Close the jar and shake it carefully until all the powder is dissolved.
Lonček zaprite in ga previdno stresajte, dokler se prašek ne raztopi.
Close the label sealing the used patch within and discard, keeping out of reach of children.
Nalepko za uporabljene obliže prilepite nazaj in zavrzite tako, da obliž ne bo dosegljiv otrokom.
Close the lid and shake hard for at least 90 seconds until all the lumps have dissolved.
Zaprite pokrovček in močno stresajte vsaj 90 sekund, dokler se vse grudice ne raztopijo.
Close the lid to seal the mixing cup.
Posodico za mešanje dobro zaprite s pokrovom.
Close the medicine reservoir by aligning the tabs of the medicine cap with the slots of the reservoir (a).
Zaprite vsebnik za zdravilo tako, da poravnate jezičke pokrova za zdravilo z zarezami na vsebniku (a).
Close the tab on the reclosable bottle cap adapter.
Zaprite jeziček zamaška z nastavkom za brizgo.
Close tightly after each use.
Po vsaki uporabi tubo tesno zaprite.
Close your mouth and hold your breath for 5 seconds.
Zaprite usta in za 5 sekund zadržite sapo.
Close: Breathe out gently and close the mouthpiece cover
Zaprite: Rahlo izdihnite in zaprite pokrovček ustnika.
Closed pouches of fluid within the kidneys (kidney cysts).
zaprti mešički tekočine v ledvicah (ledvične ciste)
Closed shoes: for feet.
Zaprte čevlje: za stopala.
closely for a decreased VPA
lopinavir/ritonavir podobno
Closer monitoring of patients with hypothyroidism co-administered with sevelamer carbonate and levothyroxine is recommended (see section 4.5).
Priporoča se skrbno nadziranje bolnikov s hipotiroidizmom, ki dobivajo sevelamerijev karbonat sočasno z levotriroksinom (glejte poglavje 4.5).
closing of the throat, difficulty swallowing
zamašitev grla, težave s požiranjem
Closing the potassium channel induces depolarisation of the beta cell and results – by opening of calcium channels – in an increased influx of calcium into the cell.
Zaprtje kalijevih kanalčkov povzroči depolarizacijo celic beta in z odprtjem kalcijevih kanalčkov poveča dotok kalcija v celice.
Clostridium difficile associated diarrhoea
Diareja, povezana z bakterijo Clostridium difficile
Clostridium difficile associated diarrhoea (CDAD) has been reported for tedizolid phosphate (see section 4.8).
Pri uporabi tedizolid fosfata so poročali o pojavu diareje, povezane z bakterijo Clostridium difficile (CDAD – Clostridium difficile associated diarrhoea) (glejte poglavje 4.8).
Clostridium difficile colitis
kolitis zaradi okužbe s
Clostridium difficile colitis (see section 4.4)
pogostnost kolitis zaradi Clostridium difficile (glejte poglavje 4.4)
Clostridium difficile colitis; Mycobacterial infection (including tuberculosis); Epstein-Barr virus infection
s Clostridium difficile povzročen kolitis, okužba z mikobakterijami (vključno s tuberkulozo), okužba z virusom Epstein- Barr
Clostridium difficile-associated diarrhoea
Diareja, ki jo povzroča bakterija Clostridium difficile
Clostridium difficile-associated diarrhoea
Diareja, povezana s Clostridium difficile
Clostridium difficile-associated diarrhoea
Driska zaradi bakterije Clostridium difficile
Clostridium difficile-associated diarrhoea (CDAD) has been reported with Cubicin (see section 4.8).
Pri uporabi zdravila Cubicin so poročali o diareji, ki jo povzroča bakterija Clostridium difficile (Clostridium difficile associated diarrhoea - CDAD) (glejte poglavje 4.8).
Clostridium difficile-associated diarrhoea has been reported with ceftazidime/avibactam, and can range in severity from mild to life-threatening.
Med zdravljenjem s ceftazidimom/avibaktamom je bila opisana driska zaradi Clostridium difficile, ki lahko sega od blage do smrtno nevarne.
Clostridium perfringens Type A alpha toxoid Not less than 6.8 IU *
Clostridium perfringens tipa A, toksoid alfa ne manj kot 6,8 i.e.
Clostridium perfringens Type A alpha toxoid: ≥ 6.8 IU* Light mineral oil: 0.31 ml
Clostridium perfringens tipa A, toksoid alfa: ≥ 6,8 i.e.* Lahko mineralno olje: 0,31 ml
Clostridium perfringens, a bacterium which may be involved in the development of ERE, isolated from rabbits with ERE showed MIC90 values of 0.5 g/ml.
Clostridium perfringens, bakterija, ki je morda vpletena v razvoj epizootične enteropatije kuncev, izoliran iz kuncev z ERE, je pokazal vrednosti MIC90 0,5 g/ml.
Clostridium tetani toxoid ............................................................................................................. ≥ 30 IU
Clostridium tetani toksoid. ........................................................................................................... ≥ 30 IU
closure and
zaprta z
Closure of the potassium channels leads to depolarisation of the beta cell and results by opening of the calcium channels – to an increased influx of calcium into the cell.
Zaprtje kalijevih kanalčkov povzroči depolarizacijo celic beta in z odprtjem kalcijevih kanalčkov poveča dotok kalcija v celice.
clotting of an artificial kidney
zamašitev umetne ledvice
Clotting parameters (e.g.
Rivaroksaban vpliva na teste strjevanja krvi (npr.
cloudiness of the eye surface (transient corneal opacity) yellowing of the skin or whites of the eyes (jaundice).
motnost površine očesa (prehodna motnost roženice) porumenelost kože ali beločnice (zlatenica)
clouding of the lens (cataract)
zamotnitev leče (katarakta)
clouding of the lens due to injury (traumatic cataract)
motnjave leče zaradi poškodbe (travmatska katarakta)
clouding of the lens due to injury (traumatic cataract),
motnjave leče zaradi poškodbe (travmatska katarakta)
Clouding of the lens of the eye.
zamegljenost očesne leče
Clouding of your eye (cataract)
zamotnitev očesa (katarakta);
cloudy area in the lens of the eye (cataracts),
zamotnitev očesne leče (katarakta),
Cloudy eyes
motne oči
cloudy lens in the eye (cataract)
motnost očesne leče (katarakta)